Indraprastha Medical Corporation Limited (NSE:INDRAMEDCO)
569.85
+5.90 (1.05%)
Oct 29, 2025, 3:30 PM IST
NSE:INDRAMEDCO Revenue
Indraprastha Medical Corporation had revenue of 3.65B INR in the quarter ending June 30, 2025, with 4.94% growth. This brings the company's revenue in the last twelve months to 13.74B, up 6.80% year-over-year. In the fiscal year ending March 31, 2025, Indraprastha Medical Corporation had annual revenue of 13.56B with 8.97% growth.
Revenue (ttm)
13.74B
Revenue Growth
+6.80%
P/S Ratio
3.80
Revenue / Employee
4.53M
Employees
3,035
Market Cap
52.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 13.56B | 1.12B | 8.97% |
| Mar 31, 2024 | 12.45B | 1.46B | 13.29% |
| Mar 31, 2023 | 10.99B | 2.11B | 23.70% |
| Mar 31, 2022 | 8.88B | 2.75B | 44.80% |
| Mar 31, 2021 | 6.13B | -2.17B | -26.17% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Aurobindo Pharma | 320.25B |
| Cipla | 274.80B |
| Zydus Lifesciences | 236.08B |
| Apollo Hospitals Enterprise | 225.51B |
| Glenmark Pharmaceuticals | 134.56B |
| Alkem Laboratories | 133.04B |
| Mankind Pharma | 129.10B |
Indraprastha Medical Corporation News
- 22 days ago - Top gainers today: Indraprastha Medical up 12.94%, Shaily Engineering up 10.06%, RHI Magnesita India up 8.27%, DOMS Industries up 5.56%, GMM Pfaudler up 5.26% as of 11 AM - Business Upturn